Vilon

Bioregulators Research compound (not approved for human use)

Synthetic dipeptide bioregulator (Lys-Glu) · also known as KE, Lys-Glu

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Vilon is the smallest of the Khavinson peptides, modeled on thymus-derived signaling fragments. It has been studied in cell culture and rodents for immune and aging endpoints; human evidence is minimal.

Commonly reported dosing (20 mg vial)

Reconstituted with 3 mL → 6.667 mg/mL.

Phase	Dose	Volume	U-100 units
Starting Below about 2 units on a U-100 syringe at this concentration; not reliably measurable.	67 mcg	0.01 mL	1
Standard	333 mcg	0.05 mL	5
Higher	667 mcg	0.1 mL	10

Frequency: Once daily for 5 consecutive days, then about 23 days off (community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

Reported in cell studies to raise CD5-positive lymphocyte numbers and IL-2 expression and to modulate inflammatory signaling in macrophages (STAT1); this is a proposed mechanism.

Researched for

Studied in mice for effects on spontaneous tumor growth and life span.
Examined in cultured lymphocytes, macrophages and stem cells for immune and gene-expression effects.
Investigated for modulation of IL-2 gene expression in rat hypothalamus.

Notes

The pulsed schedule is borrowed from other short bioregulator protocols rather than from a vial-based trial.
Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.